A b s t r a c t
Acute myeloid leukemia (AML) with inv(16)(p13q22), also known as M4Eo, is a distinct type of AML with a favorable prognosis associated with abnormal bone marrow eosinophils. We reviewed the morphologic findings of archival bone marrow specimens with M4Eo
, specifically assessing for dysplasia, and performed immunohistochemical studies to assess the growth fraction using the MIB-1 antibody. We also assessed the apoptotic rate by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-nick end labeling. All assessable cases had more than 10% dysplastic forms in at least 1 lineage. Seventeen cases had 10% or more dysplastic forms, and 3 cases had more than 50% dysplastic forms in at least 2 lineages.
Immunoreactivity for Ki-67 was higher in M4Eo than in other AML types (P = .000). The apoptotic rate in M4Eo was similar to other AML types (P = .724). Our data show that dysplasia is a prominent feature, but not a prognostic indicator, in M4Eo. M4Eo is associated with a significantly higher proliferation rate than other AML types.
It has been 20 years since acute myeloid leukemia (AML) with inv(16)(p13q22), also known as M4Eo, was recognized as a distinct type of AML with specific morphologic, genetic, and clinical features. 1, 2 In the recently published World Health Organization (WHO) classification, this neoplasm is listed as one of the 4 entities in the category of "AML with recurrent genetic abnormalities." 3 In addition to a high blast count, M4Eo is characterized by monocytosis and eosinophilia in bone marrow, with abnormal eosinophils containing large basophilic granules. 1, 2, [4] [5] [6] The inv(16)(p13q22) or, less commonly, t(16;16)(p13;q22), results in the fusion of 2 genes: CBFβ at 16q22, which encodes the β subunit of the core binding factor (CBFβ), and the MYH11 gene at 16p13, which encodes the smooth muscle myosin heavy chain (SMMHC). 7, 8 The chimeric gene CBFβ-MYH11 fuses most of the 5' coding region of CBFβ in frame with the 3' portion of MYH11, resulting in production of the chimeric protein CBFβ-SMMHC. The role of CBFβ-SMMHC in leukemogenesis remains unknown.
Although the association of M4Eo with relatively good prognosis observed in early studies was questioned, 6 it has been confirmed in later larger studies. [9] [10] [11] Cytogenetic abnormalities in addition to the characteristic inv(16)(p13q22) or t(16;16)(q13;q22) are seen commonly in M4Eo, but their presence does not modify the outcome of these patients. 9, 10 It is noteworthy that many of these additional cytogenetic abnormalities are known to be associated frequently with myelodysplasia, a feature considered an unfavorable prognostic indicator in AML. In our practice, we frequently have observed dysplastic changes in M4Eo cases. Such changes also have been recognized by others, 4, 12 but the presence of dysplasia in M4Eo is underappreciated in the literature, and its correlation with cytogenetic abnormalities and patient outcome is not known.
Expression of CBFβ-SMMHC as result of the inv(16)(p13q22) or t(16;16)(p13;q22) may promote leukemogenesis through alteration of tumor cell proliferation and apoptosis. It has been shown that the leukemic cell proliferation rate has prognostic significance, 13 as does the apoptotic rate. 14 The higher the proliferation rate and the lower the apoptotic rate, the worse the prognosis. It is well known that M4Eo is associated frequently with a high peripheral blood cell count and bone marrow hypercellularity, 1, 4, 15 suggestive of high proliferation, a low rate of apoptosis, or both. However, systematic evaluation of tumor cell proliferation and apoptosis is lacking in M4Eo cases.
We report the results of clinical and morphologic review of 21 cases of M4Eo with evaluation of tumor cell proliferation and apoptosis. Our data show that prominent dysplasia is a common feature in M4Eo, despite its favorable prognosis. In addition, the neoplastic cells of M4Eo have a high rate of proliferation compared with other types of AML.
Materials and Methods
We reviewed archival diagnostic bone marrow specimens from 21 cases of AML with inv(16)(p13q22), henceforth referred to as M4Eo, accessioned at The University of Texas M.D. Anderson Cancer Center (Houston) from October 1994 to January 2003. Bone marrow aspirate smears were available for 20 cases and biopsy sections for all cases. In 9 cases, peripheral blood smears also were available. Medical records of all patients were reviewed.
Morphologic Examination and Cytochemical Stains
Wright-Giemsa-stained bone marrow aspirate and peripheral blood smears and H&E-stained sections from biopsy specimens were examined by light microscopy. Cytochemical assays performed on smears included myeloperoxidase (using benzidine and hydrogen peroxide) and nonspecific esterase (alpha-naphthyl butyrate) activity.
Evaluation of Dysplasia
Dysplasia of hematopoietic cells was evaluated according to the morphologic criteria described in the WHO classification. 16 Dysplasia in neutrophils included hypogranular cytoplasm, hyposegmented nuclei (pseudo-Pelger-Huët anomaly), or bizarrely segmented nuclei. Dysplasia in erythroid precursors included megaloblastic nuclei, karyorrhexis, nuclear fragmentation, or multinucleation. Dysplasia in megakaryocytes included micromegakaryocytes or those with monolobed or multiple separated nuclei. For the myeloid and erythroid lineages, when possible, more than 100 cells were evaluated; cases with fewer than 20 cells assessable were defined as inadequate. For the megakaryocytic lineage, as many cells as possible were examined; cases with fewer than 5 megakaryocytes assessable were defined as inadequate.
Mitotic Figure Scoring
Mitotic figures were counted per high-power field (HPF) in areas with 100% cellularity using an Olympus BX40 microscope with 40× objective and 10× ocular (Olympus, Melville, NY). In all cases, there were sufficient areas with adequate morphology to cover 4 or more HPFs. By using this approach, 0.23 mm 2 /HPF contained approximately 2,950 cells when the cellularity was 100%. A score derived from a less cellular field was normalized proportionally to 100% cellularity (eg, when 2 mitotic figures were identified in an HPF with cellularity of 50%, a score of 4 was recorded). The median score for each case was used for final analysis.
Immunohistochemical Analysis
Immunohistochemical studies were performed by using formalin-or B5-fixed, paraffin-embedded tissue sections of the bone marrow core biopsy specimens and the MIB-1 antibody (Ki-67, 1:50 dilution; DAKO, Carpinteria, CA) using a standard avidin-biotin-peroxidase complex method as described previously. 17, 18 After heat-induced antigen retrieval, the immunostaining procedure was carried out in an autostainer (DAKO) at room temperature. The reaction was visualized by using 3-amino-9-ethylcarbazole as the chromogen. The slides were counterstained with hematoxylin. At least 500 hematopoietic cells were evaluated for nuclear staining in each case.
TUNEL Assay
A modified terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP)-nick end labeling (TUNEL) assay was used as described previously. 18, 19 Briefly, deparaffinized tissue sections were pretreated with Proteinase K for 25 minutes at 37°C and then incubated for 5 minutes in 3% hydrogen peroxide in phosphate-buffered saline, pH 7.4, to block endogenous peroxidase activity. TdT (New England Biolabs, Beverly, MA) was applied subsequently (15 U per slide) for 1 hour, at 37°C in 20-mmol/L tris(hydroxymethyl)aminomethane-acetate (pH 7.9), 50-mmol/L potassium acetate, 10-mmol/L magnesium acetate, 1-mmol/L dithiothreitol, 0.25-mmol/L cobalt chloride, and 24-µmol/L biotin-deoxyadenosine triphosphate (dATP) (Life Technologies, Gaithersburg, MD). The TUNEL assay was modified by substituting dUTP for dATP. Streptavidin-biotin-horseradish peroxidase complex (LSAB+ kit) and 3,3'-diaminobenzidine (both from DAKO) were used for detection. The slides were counterstained with hematoxylin.
Apoptotic figures, including positively labeled intact nuclei and nuclear fragments derived from a single cell, were counted in the same way as for mitotic figures (see "Mitotic Figure Scoring").
Conventional Cytogenetics and Fluorescence In Situ Hybridization
Conventional G-band karyotype analysis was performed on all samples. The karyotype formula was written according to the International System for Human Cytogenetic Nomenclature. 20 We confirmed the cytogenetic findings in some cases by using fluorescence in situ hybridization (FISH) and a Vysis CBFβ inv(16) dual color breakapart DNA probe (Vysis, Downers Grove, IL). This probe hybridizes to band 16q22 (spectrum red on the centromeric side and spectrum green on the telomeric side of the CBFβ breakpoint). A split signal confirms the presence of a breakpoint at 16q22 consistent with inv(16)(p13q22).
Reverse Transcription-Polymerase Chain Reaction
Reverse transcription-polymerase chain reaction (RT-PCR) methods for detection of CBFβMYH11 fusion transcripts have been described previously. 21 
Statistics
The Student t test was applied to compare the differences in blast count, cellularity, mitotic figures, Ki-67 reactivity, and TUNEL results between M4Eo and other types of AML.
Results

Clinical Features
The clinical features for the 21 patients are summarized in ❚Table 1❚. There were 10 men and 11 women whose ages ranged from 19 to 75 years (median, 36 years). Five patients had a malignant neoplasm treated with chemotherapy, radiation, or both before the diagnosis of M4Eo. Thirteen patients (62%) had nonspecific symptoms (weakness, fatigue, dizziness, or gastrointestinal symptoms); these were the only symptoms in 6 patients. Fever, infection, or both in 8 patients and bruising, bleeding, or both in 4 patients also were common. The diagnosis of M4Eo in 3 patients was an incidental finding after detection of an abnormal peripheral blood leukocyte count. No patients had clinically identifiable extramedullary disease at the time of diagnosis.
Most patients received cytarabine-based chemotherapy in combination with fludarabine, daunorubicin, or idarubicin. Two patients (cases 1 and 7) were in their first course of chemotherapy at last follow-up, and 2 patients (cases 4 and 15) died shortly after initiation of chemotherapy, both secondary to infection and cardiopulmonary failure. One patient (case 18) was transferred to another hospital after diagnosis and was lost to follow-up. Sixteen patients who completed induction chemotherapy had complete remission. Ten patients were still in complete remission, with 3 having exceeded 24 months, at the time of last follow-up. The remaining 6 patients had relapse after a median of 19 months, but all achieved a second remission. One patient (case 14) had a second relapse, and another (case 8) had 3 relapses. All patients had leukemia in the bone marrow, peripheral blood, or both at the time of relapse. Thirteen (81%) of 16 patients were alive at the last follow-up (median follow-up, 24 months). Three patients died with a median survival of 23 months. One patient (case 19) died of signet-ring cell carcinoma, 1 (case 8) died of endometrial carcinoma; both were in complete remission. The third (case 2) died of hepatic failure due to graft-vs-host disease and toxic hepatitis.
Peripheral Blood Findings
As shown in ❚Table 2❚, most patients had leukocytosis, anemia, and thrombocytopenia. The leukocyte count ranged Peripheral blood smears were available for 9 patients, and 8 showed dysplastic neutrophils ❚Image 1A❚. Eosinophils were morphologically normal in all cases except one in which eosinophils contained cytoplasmic vacuoles. Slight red cell anisocytosis was noted in some cases. Platelets were morphologically normal in all 9 cases reviewed.
Bone Marrow Findings
The findings in bone marrow aspirate smears included increased blasts, monocytic differentiation, and eosinophilia with abnormal forms ❚Table 3❚. Blast counts ranged from 25% to 80% (median, 50%). Auer rods were identified in the blasts of 4 cases. Blasts were positive for myeloperoxidase in all cases tested (range, 69%-100% of cells; median, 90%), but they had a lower positivity rate for nonspecific esterase (range, 5%-35% of cells; median, 20%). Monocytes represented 4% to 55% (median, 14%) of all nucleated cells. Immature monocytes were seen frequently. Eosinophil counts ranged from 4% to 30% (median, 10%) with 12% to 100% (median, 40%) of the forms showing characteristic large basophilic granules.
Dysplasia was observed frequently in bone marrow smears ❚Image 1B❚ and ❚Image 1C❚. Dysplastic forms constituted 50% to 93% (median, 80%) of granulocytes in 14 assessable cases, 0.69% to 86% (median, 27.5%) of erythroid cases were similar to those of M4Eo cases (range, 7%-85%; median, 49%; P = .567). Cellularity varied from 25% to 100% (median, 80%), lower than that of M4Eo cases (P =.002). Mitotic figures ranged from 0 to 5/HPF (median, 2/HPF) and Ki-67 positivity ranged from 8% to 100% (median, 50%), both significantly lower than that of the M4Eo cases (P = .003 and P = .000, respectively). The 2 AML M6 cases in this group showed the highest number of Ki-67-immunoreactive cells (100% and 85%, respectively) owing to a high growth fraction in the erythroid lineage. 22 The TUNEL assay stained from 3 to 36 apoptotic figures per HPF (median, 9.5/HPF), similar to the results for M4Eo (P = .724). Comparison of various features of M4Eo and other types of AML is summarized in ❚Table 5❚. The 2 normal bone marrow cases showed 35% cellularity, 0 mitotic figures per HPF, 41% and 45% Ki-67 immunoreactivity, and 35 and 36 apoptotic figures per HPF, the latter being higher than in any of the M4Eo or other AML cases.
Cytogenetic and Molecular Results
Conventional cytogenetic studies were performed in all 21 cases; 18 were positive for inv(16)(p13q22), 2 were positive for t(16;16)(p13;q22), and 1 was negative ❚Table 6❚. The single case negative by conventional cytogenetics was also negative by FISH but was positive by RT-PCR. Additional cytogenetic abnormalities were seen in 9 cases, including trisomy 22 in 4 cases and trisomy 8 in 2 cases.
RT-PCR to detect the CBFβ/MYH11 fusion transcripts was performed in 14 cases. In all cases, a 166-base-pair product was amplified corresponding to the type A transcript. 23 
Discussion
We retrospectively evaluated the clinical and morphologic features of 21 cases of AML with inv(16)(p13q22), or t(16;16)(p13;q22), also known as M4Eo. As has been ❚Image 1❚ (cont) E, Bone marrow smear showing blasts and an abnormal immature eosinophil undergoing mitosis (WrightGiemsa, ×1,000). F, Immunostain showing nuclear reactivity in the majority of the M4Eo cells (Ki-67, ×200). G, Low rate of apoptosis in M4Eo as indicated by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-nick end labeling procedure (×200). Yes  94  22  14  5.2  32  --25  95  3  94  2  3  40  No  85  23  20  16  44  92  33  IA  90  3  97  15  4  46.2  No  94  12  12  30  94  IA  IA  IA  85  7  82  30  5 58. reported, patients typically had symptoms and signs associated with anemia, neutropenia, or thrombocytopenia. A high peripheral blood WBC count was common. Bone marrow examination revealed a high blast count and hypercellularity. In addition, prominent dysplasia was seen frequently. Patients usually achieved complete remission with chemotherapy. Dysplasia has been considered an important unfavorable prognostic factor in AML. 24 Previous studies have shown that patients in whom AML developed after diagnosis of myelodysplastic syndrome had a worse prognosis than did patients with de novo AML. 25 Similarly, patients in whom de novo AML developed accompanied by myelodysplastic changes were shown to have a worse prognosis than patients without these changes. 24, 26 Thus, it seems paradoxical that prominent dysplasia is associated with M4Eo, an entity that has been shown to have a good prognosis. 2, 5, [9] [10] [11] Authentic criteria for the extent of dysplasia in M4Eo are not available. In our series, 85% of the cases had 10% or more dysplastic forms in at least 2 lineages, meeting the criteria used for dysplasia in "refractory cytopenia with multilineage dysplasia" in the WHO classification. 27 In addition, 15% of cases had more than 50% dysplastic forms in at least 2 lineages, meeting the requirement for dysplasia used in "acute myeloid leukaemia with multilineage dysplasia." 16 Dysplasia in M4Eo does not seem to correlate with cytogenetic abnormalities that are frequently seen in myelodysplastic syndrome, such as trisomy 22 and trisomy 8. It seems likely that dysplasia in M4Eo is an intrinsic phenomenon, probably a consequence of the fusion protein CBFβ/SMMHC. Supporting this view is the finding that introduction of the fusion protein into mouse myeloid cells impaired neutrophil maturation and caused myelodysplasia. 28 Moreover, the presence of dysplasia, like the presence of additional cytogenetic abnormalities, should not be considered an indicator for poor prognosis in this type of AML, which has a specific cytogenetic-molecular abnormality associated with good prognosis. This concept is in agreement with recent findings that dysplastic morphologic features have no additional impact on predicting prognosis when cytogenetics is taken into account. 29 The proliferation rate of a neoplasm is determined by both growth fraction and generation time of tumor cells. 30 The larger the growth fraction and the shorter the generation time, the higher the proliferation rate. Our data show that M4Eo cases have high growth fractions as indicated by Ki-67 immunostaining, significantly higher than most other types of AML (M6 is the exception). It is worth noting that the high growth fraction was attributed to M4Eo tumor cells (blasts, monocytes, and abnormal eosinophils), since these cells constitute the majority of nucleated cells in the bone marrow. Erythroid precursors are known to have high rates of Ki-67 positivity and contribute substantially to the Ki-67 score in normal bone marrow. 22 Their contribution is trivial in M4Eo cases, however, since these cells were scarce. Although the tumor cell generation time was not directly assessed in the present study and progression in certain parts of the M4Eo cell cycle may be slow, 31, 32 our observations, such as high peripheral blood leukocyte counts, high blast counts in the bone marrow, hypercellularity, and brisk mitotic rate, all point to the high proliferation status of M4Eo. Such high proliferation status may account, in part, for the good response to intensive chemotherapy. Neoplasms with a high proliferation rate often have a high apoptotic rate (reviewed by Sen et al 33 ). However, the apoptotic rate in M4Eo cases generally was low. This is another paradoxical finding in M4Eo since low apoptotic rates usually are associated with poor outcome in patients with AML. 34 Britos-Bray et al 35 demonstrated that expression of CBFβ-SMMHC in Ba/F3 cells reduced p53 induction in response to ionizing radiation or etoposide and inhibited tumor cell apoptosis. Hence, a low rate of apoptosis in M4Eo seems to be another intrinsic feature, probably present as a consequence of the presence of the fusion protein.
M4Eo, despite its excellent prognosis, has findings commonly associated with a poorer prognosis in AML, including dysplasia, high proliferative activity, and a low rate of apoptosis. We suspect that the CBFβ-MYH11 fusion protein is related to those processes. 
